Masayoshi Son’s investment group touts ‘commitment to advancing US technology and manufacturing leadership’Read More

You might also be interested in reading Catalyst Pharmaceuticals reaffirms $545M-$565M 2025 revenue guidance while accelerating FIRDAPSE oncology expansion.